OncoMatch/Clinical Trials/NCT07885475
Dexmedetomidine for Refractory Pain in Palliative Cancer Patients
Is NCT07885475 recruiting? Yes, currently enrolling (Oct 2026).
The goal of this study is to find out whether the medication dexmedetomidine can be a safe and effective additional treatment for cancer patients whose pain is not well controlled by standard pain medicines (such as opioids). The study includes 30 palliative care patients who still have significant pain despite standard pain treatment. All participants will receive dexmedetomidine, and outcomes related to efficacy and safety will be systematically observed.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Prior therapy
Must have received: parenteral opioid — cancer-related pain
Treated with parenteral opioids for cancer-related pain
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07885475 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received parenteral opioid.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify